secwatch.observer — SEC 8-K summary
======================================

Issuer:     Korro Bio, Inc. (KRRO)
CIK:        0001703647
Form:       8-K
Filed at:   2022-03-31T23:59:59+00:00
Accession:  0001193125-22-092065
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CFO Peter Pfreundschuh to depart Frequency Therapeutics March 31, 2022; no successor named
--------------------------------------------------------------------------------

- CFO Peter P. Pfreundschuh stepping down effective March 31, 2022; not due to any disagreement with the Company.
- Severance includes 12 months base salary, $189,000 bonus, $20,000 relocation, and COBRA premium payments.
- As of separation, 74,790 stock options are vested and exercisable; 330,210 shares remain unvested.
- No replacement CFO has been announced; CEO David Lucchino signed the separation agreement.
- Separation agreement includes standard release of claims, confidentiality, and non-disparagement clauses.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1703647/000119312522092065/0001193125-22-092065-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1703647/000119312522092065/d309564d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-092065

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer